Perfusate hemoglobin during normothermic liver machine perfusion as biomarker of early allograft dysfunction: A pilot study
Artificial Organs · 2025
DOI: 10.1111/aor.14862 ↗Kurz gefasst
Fachartikel in der Zeitschrift Artificial Organs, 2025. Verfasst von Akinori Maeda und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care, Austin Hospital, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Liver Transplantation, Biomarkers, Perfusion, Organ Preservation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Normothermic machine perfusion (NMP) aims to reduce ischemia–reperfusion injury in donor livers and its clinical manifestation, early allograft dysfunction (EAD) by maintaining perfusion and oxygenation. However, there is limited data on which NMP perfusate biomarkers might be associated with such EAD and the role of perfusate hemoglobin has not been assessed.
Methods
We performed a pilot retrospective analysis of adult donor livers undergoing NMP between 2020 and 2022 at our center. NMP was commenced at the recipient hospital after initial static cold storage. All NMP circuits were primed in the same manner according to the manufacturer's instructions. Livers were stratified by initial perfusate hemoglobin below (≤5.2 mmol/L) or above (>5.2 mmol/L) the median. The association between hemoglobin levels and EAD or recipient peak transaminase levels was assessed.
Results
Among 23 livers, eight were considered unsuitable for transplantation, leaving 15 livers for assessment. Higher initial hemoglobin was associated with a lower risk of EAD (0% vs. 55.6%, p = 0.04). Perfusate hemoglobin decreased after NMP initiation ( p = 0.003) and negatively correlated with recipient peak transaminase levels (ALT: ρ = −0.72, p = 0.002; AST: ρ = −0.79, p < 0.001). Consistently, higher hemoglobin livers also demonstrated lower perfusate liver enzymes.
Conclusions
Perfusate hemoglobin levels decreased during NMP, and lower perfusate hemoglobin levels were associated with a higher incidence of EAD and higher levels of liver injury markers. Maintaining higher hemoglobin levels during NMP may help reduce ischemia–reperfusion injury and prevent or attenuate EAD. Larger prospective studies are needed to validate the findings of this pilot study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intensive Care, Austin Hospital, Melbourne, Victoria, Australia.
- Department of Emergency and Critical Care Medicine, The University of Tokyo, Tokyo, Japan.
- Victorian Liver Transplant Unit, Austin Hospital, Melbourne, Victoria, Australia.
- Department of Surgery, Austin Hospital, The University of Melbourne, Melbourne, Victoria, Australia.
- Australian Centre for Transplantation Excellence and Research, Austin Hosptial, Melbourne, Victoria, Australia.
- Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, Victoria, Australia.
ORCID-Profile: Akinori Maeda
Zitieren
APA
Maeda, A., Starkey, G., Spano, S., Chaba, A., Eastwood, G., Yoshino, O., Perini, M. V., Fink, M., Bellomo, R., & Jones, R. (2025). Perfusate hemoglobin during normothermic liver machine perfusion as biomarker of early allograft dysfunction: A pilot study. Artificial Organs. https://doi.org/10.1111/aor.14862
Vancouver
Maeda A, Starkey G, Spano S, Chaba A, Eastwood G, Yoshino O, et al. Perfusate hemoglobin during normothermic liver machine perfusion as biomarker of early allograft dysfunction: A pilot study. Artificial Organs. 2025. doi:10.1111/aor.14862
BibTeX
@article{Maeda2025,
author = {Maeda, Akinori and Starkey, Graham and Spano, Sofia and Chaba, Anis and Eastwood, Glenn and Yoshino, Osamu and Perini, Marcos Vinicius and Fink, Michael and Bellomo, Rinaldo and Jones, Robert},
title = {Perfusate hemoglobin during normothermic liver machine perfusion as biomarker of early allograft dysfunction: A pilot study},
journal = {Artificial Organs},
year = {2025},
doi = {10.1111/aor.14862}
}
EUVIMED